Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release
G protein-coupled receptors (GPCRs) are classically characterized as cell-surface receptors transmitting extracellular signals into cells. Here we show that central components of a GPCR signaling system comprised of the melatonin type 1 receptor (MT₁), its associated G protein, and β-arrestins are o...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 114; no. 38; pp. E7997 - E8006 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
19.09.2017
|
Series | PNAS Plus |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | G protein-coupled receptors (GPCRs) are classically characterized as cell-surface receptors transmitting extracellular signals into cells. Here we show that central components of a GPCR signaling system comprised of the melatonin type 1 receptor (MT₁), its associated G protein, and β-arrestins are on and within neuronal mitochondria. We discovered that the ligand melatonin is exclusively synthesized in the mitochondrial matrix and released by the organelle activating the mitochondrial MT₁ signal-transduction pathway inhibiting stress-mediated cytochrome c release and caspase activation. These findings coupled with our observation that mitochondrial MT₁ overexpression reduces ischemic brain injury in mice delineate a mitochondrial GPCR mechanism contributing to the neuroprotective action of melatonin. We propose a new term, “automitocrine,” analogous to “autocrine” when a similar phenomenon occurs at the cellular level, to describe this unexpected intracellular organelle ligand–receptor pathway that opens a new research avenue investigating mitochondrial GPCR biology. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC5617277 1Y.S., W.L., F.G.J.-A., J.J., N.K.K., and J.L. contributed equally to this work. Author contributions: Y.S., M.B.M., S.M.P., D.B.S., P.A.W.-E., D.L.C., J.-P.V., and R.M.F. designed research; Y.S., W.L., F.G.J.-A., J.J., N.K.K., J.L., S.V.B., D.L., A.C.M., Y.H., E.C., V.L.W., J.K., B.E.H., O.V.B., X.W., M.J.G., E.S.K., G.D.B., L.M.F., T.M.L., M.S., S.Y., J.W., and P.A.W.-E. performed research; G.G. and F.S. designed fluorescent ICOA ligands; R.M.R. and R.J. contributed new reagents/analytic tools; Y.S., T.R.L., P.A.W.-E., D.L.C., J.-P.V., and R.M.F. analyzed data; and Y.S., P.A.W.-E., D.L.C., J.-P.V., and R.M.F. wrote the paper. Edited by Robert J. Lefkowitz, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC, and approved August 16, 2017 (received for review April 6, 2017) |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1705768114 |